浙江瑞加美生物科技

Regemi is a clinical-stage biotechnology company based in Huzhou, China, specializing in the development of next-generation cell therapies. The company focuses on its proprietary Regemi-NK platform to develop off-the-shelf CAR-NK cell products for the treatment of solid tumors, including liver cancer. In addition to oncology, Regemi explores the applications of mesenchymal stem cells in regenerative medicine and inflammatory diseases. The company leverages advanced cell expansion and genetic modification technologies to improve the efficacy and persistence of innate immune cells. Regemi aims to provide accessible and effective cell-based treatments through standardized manufacturing processes.